NEWS & EVENTS

 

Auspherix Provides Update on its New Class of Organogold Antibiotics

 
Auspherix Provides Update on its New Class of Organogold Antibiotics

20 January 2017

Auspherix have provided an update on the development of their organogold antibiotic compounds, which have a unique chemical structure and a distinct antibacterial profile.  The anti-infectives company have used their chemistry expertise to develop novel chemical compounds based on auranofin which inhibit both Gram-positive and Gram-negative bacteria.

Preliminary data indicates that Auspherix’s organogold compounds possess a broad spectrum of activity against both Gram-positive and Gram-negative bacteria (including life threatening multi-drug resistant (MDR) pathogens) and show less propensity for the emergence of resistance.

Some years ago the team at Auspherix embarked on a discovery program to identify antibacterial compounds.  This research identified auranofin, an FDA approved anti-rheumatic agent, as having activity against Gram-positive bacteria in planktonic, biofilm and persister forms.

A press release from Auspherix can be found here.

Mewburn Ellis partners Robert Watson and Robert Andrews and associate Callum McGuinn advise Auspherix on their IP strategy and are working with them to develop their global patent portfolio.